Company News

EuMentis Therapeutics’ CMO Randall Marshall to Present on its novel PDE10A inhibitor for Tourette Syndrome at TicCon24

May 29, 2024
EuMentis Therapeutics, Inc. announced today that the Company’s Chief Medical Officer, Randall Marshall, MD, will be presenting at the Tourette Association of America’s TIC-CON24 Research Symposium being held on May 31st in Dallas, Texas.
Download PDF

EuMentis Therapeutics’ Chief Medical Office Randall Marshall, MD to Give Keynote Presentation at Autism Parenting Summit

May 15, 2024
EuMentis Therapeutics, Inc. announced today that the Company’s Chief Medical Officer, Randall Marshall, MD, will be presenting a keynote address at the Autism Parenting Summit being held virtually from May 17th- 20th.
Download PDF

EuMentis Therapeutics Inc. Receives $3 Million Award

February 08, 2023
EuMentis Therapeutics Inc. Receives $3 Million Award from United States Department of Defense (DoD) to Advance its Novel NMDA Receptor Antagonist for Traumatic Brain Injury.
Download PDF

EuMentis Therapeutics Inc. Announces Company Launch

February 13, 2020
EuMentis Therapeutics Inc. Announces Company Launch and Focus on Developing Novel Therapeutics to Treat High Value Neurodevelopmental and Neurodegenerative Diseases
Download PDF
Privacy Policy
Terms & Conditions
Contact
© 2021 EuMentis Therapeutics. All Rights Reserved.